Apr 06,2023

Baptist Health Miami Cancer Institute expands partnership with COTA

Baptist Health Innovations and COTA’s collaboration has added new technology for cancer care. This partnership provides physicians with real-world evidence (RWE) for cancer care, allowing them to look at data from many levels and analyze the cost-effectiveness of healthcare services. Miami Cancer Institute used COTA’s analysis of RWE to change its testing policy for breast cancer gene mutations.

COLLABORATION PARTNERSHIP

#institution

#rwe

View Analyst & Ambassador Comments
Go to original news
Mar 31,2023

NCCN: Enabling real-world cancer research with real-world data from COTA

Some of COTA Healthcare's latest work has been accepted for presentation at the National Comprehensive Cancer Network (NCCN) 2023 Annual Conference. NCCN is the organization responsible for stewarding cancer care guidelines and standards of care. Using novel real-world data (RWD), such as EHR data, claims, and registry information, researchers and clinicians can uncover hidden patterns in cancer care and treatment models.

#rwd

#rwe

View Analyst & Ambassador Comments
Go to original news
Aug 30,2022

Syapse and Genesis Research Form RWE Partnership in Oncology

Today, Syapse, a leading real-world evidence company dedicated to extinguishing the fear and burden of serious diseases, announced that they have entered into a strategic partnership with Genesis Research. As part of the partnership, Genesis Research will leverage Syapse’s leading real-world evidence platform, enabling the two companies to develop a deeper understanding of the challenges associated with complex cancers. Together, this relationship will enable Syapse to provide its clients access to Genesis’ integrated research partnerships.  

COLLABORATION PARTNERSHIP

#product & service

#rwd

#rwe

View Analyst & Ambassador Comments
Go to original news
Mar 03,2020

Sema4 and VieCure collaborate to provide real-time patient insights

Health intelligence company Sema4 and artificial intelligence (AI) informatics company VieCure have entered a strategic collaboration to enable oncologists to provide personalised care to the patients. The alliance allows Sema4 scientists to access patient data from the VCurePrecision EMR platform with the consent of the patients and analyse the data using its Centrellis health intelligence platform. Furthermore, it will allow oncologists using the VCurePrecision EMR to access real-time insights that help in point-of-care decision-making and clinical trial identification for patients. This strategic collaboration also enables healthcare providers to recommend Sema4’s molecular testing for cancer through the VCurePrecision platform.

COLLABORATION PARTNERSHIP

#data & technology

#rwd

#rwe

View Analyst & Ambassador Comments
Go to original news
Mar 02,2023 TOP STORY

Chugai and Biofourmis Enter into New Partnership Focused on Data-Driven Virtual Care for Endometriosis-Related Pain

Chugai Pharmaceutical Co., Ltd. and Biofourmis, announced that they have entered into a new partnership agreement for the continued development and real-world use of digital solutions to objectively measure pain in patients with endometriosis. The two companies have been collaborating on developing a new objective assessment of pain in patients with endometriosis using a biosensor and an AI-based algorithm utilizing Biofourmis’ Biovitals® platform since July 2020. Since pain is a subjective symptom, it can be difficult to accurately convey to family members and healthcare professionals the degree of pain patients experience. Further advances in pain quantification technologies in endometriosis patients could lead to a better understanding of the pathology, to guide appropriate medical care and advance clinical trials. By providing new digital solutions, Chugai aims to further enhance its value propositions for endometriosis patients.

COLLABORATION PARTNERSHIP

#r&d

#software

#rwe

View Analyst & Ambassador Comments
Go to original news
Mar 03,2023

Development and validation of an electronic daily control score for asthma (e-DASTHMA): a real-world direct patient data study

Validated questionnaires are used to assess asthma control over the past 1–4 weeks from reporting. However, they do not adequately capture asthma control in patients with fluctuating symptoms. Using the Mobile Airways Sentinel Network for airway diseases (MASK-air) app, this study developed and validated an electronic daily asthma control score (e-DASTHMA). e-DASTHMA is a good tool for the daily assessment of asthma control. This tool can be used as an endpoint in clinical trials as well as in clinical practice to assess fluctuations in asthma control and guide treatment optimisation.

CLINICAL STUDY

#mobile app

#rpm

#rwe

View Analyst & Ambassador Comments
Go to original news
Jan 24,2023

How Real-World Data Helps Explore Alternative Dosing for Colorectal, Pancreatic Cancer Therapy

A joint effort between MedStar Georgetown Lombardi Comprehensive Cancer Center and COTA has demonstrated the feasibility of a patient-oriented dosing schedule for Stage 4 CRC/PC or locally advanced PC. This partnership showcases the contribution of real-world data to clinical research, which can provide insights into care that is currently being administered in clinical settings and help address critical questions.

CLINICAL STUDY

#rwd

#rwe

View Analyst & Ambassador Comments
Go to original news
Jan 07,2020

Pear Therapeutics Expands Pipeline With Licenses of CBT and Biomarker Technologies

Pear Therapeutics announced today that it has entered into mulitple agreements with technology innovators, including NeuroLex Laboratories developing a biomarker platform for mental health problems, leading researchers from the Karolinska Institute in Sweden developing content for clinical stage DTx, Cincinnati Children’s Hospital Medical Center developing CBT and patient education against migraines, and lastly Winterlight Labs, Inc. developing a technology that analyzes and assesses cognitive health. These new agreements continue to bolster Pear’s PDT platform, by adding to its library of digital biomarkers, machine learning algorithms, and digital therapeutics.

COLLABORATION PARTNERSHIP

#r&d

#rwe

#pdt

View Analyst & Ambassador Comments
Go to original news
Jun 11,2019

DarioHealth Reports Improvement in Glycemic Outcomes With Key Diabetes Findings at the American Diabetes Association's 79th Scientific Sessions

DarioHealth Corp. (NASDAQ: DRIO), a leading global Digital Therapeutics (DTx) company with connected devices, mobile software and large data solutions presented two studies reporting new real-world results at the American Diabetes Association's (ADA) 79th Scientific Sessions in San Francisco, California. The results of the studies highlight that for 4,917 T2D users measuring more than 15 times per month, the average of % in-range readings (70-140 mg/dL) was increased in correlation to app engagement (occurrences of tagging meals, carbs, physical activity).

CLINICAL STUDY

#rwe

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jan 20,2022

Health2Sync Expands Product Offering In Chronic Disease Management With Real Word Data Integration And Analytics

Taiwan-based digital health startup Health2Sync makes further inroads in personalized chronic disease management with an expanded coverage of the patient journey with the latest version of its mobile application capturing continuous glucose monitoring (CGM) data to improve overall lifestyles, and its recently announced plan to commercialize digital therapeutics (DTx) targeting insulin management for diabetics with Sanofi.

PRODUCT

#mobile app

#rwe

View Analyst & Ambassador Comments
Go to original news
Subscribe to RWE